多西他赛联合表柔比星方案化疗对三阴性乳腺癌患者p53及血管内皮生长因子的影响

Influence of Docetaxel combined with Epirubicin regimen chemotherapy on p53 and vascular endothelial growth factor in patients with triple negative breast cancer

目的 研究多西他赛联合表柔比星方案化疗治疗三阴性乳腺癌(TNBC)患者的效果及对肿瘤抑制蛋白p53(p53)、血管内皮生长因子(VEGF)的影响.方法 选取2013年1月~2015年12月我院收治的124例女性TNBC患者作为研究对象,按照随机数字表法将其分为实验组(n=62)与对照组(n=62).对照组患者行环磷酰胺联合表柔比星方案化疗,实验组患者行多西他赛联合表柔比星方案化疗.观察两组患者治疗前后血清VEGF亚型(VEGF A、VEGF B、VEGF C)水平、p53阳性表达率,比较两组患者的临床疗效、1~3年生存率及毒副作用发生情况.结果 治疗后,实验组患者的VEGF A、VEGF B、VEGF C水平均低于对照组,差异有统计学意义(P<0.05).实验组患者治疗后的p53阳性表达率低于对照组,客观有效(OR)率高于对照组,差异有统计学意义(P<0.05).两组患者1、2年生存率比较,差异无统计学意义(P>0.05);实验组患者的3年生存率高于对照组,差异有统计学意义(P<0.05).两组患者的毒副作用发生率比较,差异无统计学意义(P>0.05).结论 多西他赛、表柔比星新辅助化疗可有效杀灭TNBC,抑制VEGF各亚型及p53表达,3年生存率高,毒副作用少,安全可靠.

Objective To study the effect of Docetaxel combined with Epirubicin regimen chemotherapy in the treatment of triple negative breast cancer(TNBC)and influence on tumor suppressor protein p53(p53)and vascular endothelial growth factor(VEGF).Methods A total of 124 female TNBC patients admitted to our hospital from January 2013 to December 2015 were selected as the research subjects,and they were divided into experimental group(n=62)and control group(n=62)according to the random number table method.The Control group received Cyclophosphamide combined with Epirubicin regimen chemotherapy,while the experimental group received Docetaxel combined with Epirubicin regimen chemotherapy.The levels of serum VEGF subtypes such as VEGF A,VEGF B,VEGF C and p53 positive expression rates were observed before and after treatment in the two groups.The clinical efficacy,1 to 3-year survival rates and incidence of toxic and side effect in the two groups of patients were compared.Results After treatment,the levels of VEGF A,VEGF B,and VEGF C in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,the positive expression rate of p53 in the experimental group was lower than that in the control group,and the objective response(OR)rate was higher than that in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the 1-and 2-year survival rates between the two groups of patients(P>0.05).The 3-year survival rate in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of toxic and side effect between the two groups of patients(P>0.05).Conclusion Neoadjuvant chemotherapy with Docetaxel and Epirubicin can effectively kill TNBC,and inhibit the expression of VEGF subtypes and p53.The 3-year survival rate is high,the toxic and side effect is less,and it is safe and reliable.